Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2010

View Archived Issues

BNC-210 is well tolerated in healthy volunteers

AZ-004 is efficacious in preclinical model of inflammatory pain

Rivaroxaban is as effective as standard therapy in treating deep vein thrombosis

Oral JNJ-41876666 is active against cold allodynia in models of neuropathic pain

New glucagon receptor antagonists claimed by Merck & Co.

Abbott presents new inhibitors of GlyT-1

Shionogi recaps Q1 highlights of fiscal year 2010

New alpha2C-adrenoceptor agonists display antinociceptive effects and cardiovascular safety in vivo

Patient enrollment complete in Antisoma's phase III trial of AS-1413

BMS acquires ZymoGenetics and PEG-interleukin-29 for HCV infection

Transgene and Jennerex enter into exclusive partnership for JX-594

Sylentis to begin new phase I/II trial of SYL-040012 for elevated IOP and glaucoma

NeuroSearch discloses new voltage-gated potassium channel activators

GSK presents new dual histamine H1/H3 receptor antagonists

Merck & Co. discontinues development of MK-6913 for hot flashes

Taisho Pharmaceutical claims new selective SGLT1 inhibitors

N30 Pharma begins dosing in first-in-human phase I trial of N-6022

FDA advisory committee recommends approval of ceftaroline fosamil for CABP and cSSSI

Cempra begins studies of oral and intravenous solithromycin

Phase III trial begins of oral methylnaltrexone in opioid-induced constipation

FDA approves expanded indications for Saphris

Condition for approval removed for Avastin in Japan

Mylan acquires Bioniche Pharma ahead of schedule

Emergent BioSolutions begins phase I trial of inhalational anthrax treatment

FDA approves Abbott RealTime HBV assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...